Rein Therapeutics
RNTX
19 hedge funds and large institutions have $20.7M invested in Rein Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
12.64% more ownership
Funds ownership: 0% → 12.64% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$7.33M |
| 2 |
Jennison Associates
New York
|
+$2.74M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.65M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.37M |
| 5 |
Millennium Management
New York
|
+$1.34M |
Top Sellers
RNTX Hedge Fund Activity: Q2 2017 in Review
19 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2017, worth a combined $20.7M.
Buyers outnumbered sellers: 19 funds opened new RNTX positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $7.33M.
- 19 institutional investors held Rein Therapeutics (RNTX) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $20.7M of Rein Therapeutics stock for Q2 2017.
- 19 funds opened new Rein Therapeutics positions in Q2 2017 and 0 closed out, a net change of +19 holders.
- The largest Rein Therapeutics buyer in Q2 2017 was Bank of America, an estimated $7.33M added.
Based on aggregated 13F filings for Q2 2017.